PMID- 34039310
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20240402
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 May 26
TI  - Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of 
      cancers: an update evidence from 14 studies.
PG  - 618
LID - 10.1186/s12885-021-08363-w [doi]
LID - 618
AB  - BACKGROUND: CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is 
      expressed on the surface of effector Tregs that have the highest suppressive 
      effects on antitumor immune response. CCR4 is also widely expressed on the 
      surface of tumor cells from patients with adult T-cell leukemia/lymphoma (ATL), 
      peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). 
      Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed 
      against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the 
      mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve 
      antitumor effects. METHODS: We examined the PubMed and ClinicalTrials.gov until 1 
      February 2020. Considering variability in different studies, we selected the 
      adverse events (AEs), overall survival (OS), progression-free survival (PFS), 
      objective responses rate (ORR) and Hazard Ratio (HR) for PFS to evaluate the 
      safety and efficacy profile of mogamulizumab. RESULTS: When patients were treated 
      with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, 
      infusion reaction, fever, rash and chills while the most common grade >/= 3 AEs 
      were lymphopenia, neutropenia and rash. When patients were treated with combined 
      therapy of mogamulizumab and other drugs, the most common all-grade AEs were 
      neutropenia, anaemia, lymphopenia and gastrointestinal disorder, while the most 
      common grade >/= 3 AEs was lymphopenia. For patients treated with mogamulizumab 
      monotherapy, the pooled ORR and mean PFS were 0.430 (95% CI: 0.393-0.469) and 
      1.060 months (95% CI: 1.043-1.077), respectively. For patients treated with 
      combined therapy of mogamulizumab and other drugs, the pooled ORR was 0.203 (95% 
      CI: 0.022-0.746) while the pooled PFS and OS were 2.093 months (95% CI: 
      1.602-2.584) and 6.591 months (95% CI: 6.014-7.167), respectively. CONCLUSIONS: 
      Based on present evidence, we believed that mogamulizumab had clinically 
      meaningful antitumor activity with acceptable toxicity which is a novel therapy 
      in treating patients with cancers.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Cancer Center, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 
      610041, Sichuan, China.
AD  - West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 
      China.
FAU - Sun, Jing
AU  - Sun J
AD  - Qingdao central hospital, Qingdao University, Qingdao, Shandong, China.
FAU - Li, Jinying
AU  - Li J
AD  - Department of radiotherapy, Qingdao central hospital, Qingdao University, 
      Qingdao, Shandong, China.
FAU - Zhao, Yunuo
AU  - Zhao Y
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Cancer Center, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 
      610041, Sichuan, China.
AD  - West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 
      China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Cancer Center, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 
      610041, Sichuan, China.
AD  - West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 
      China.
FAU - Yang, Ruoning
AU  - Yang R
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Cancer Center, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 
      610041, Sichuan, China.
AD  - West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 
      China.
FAU - Ma, Xuelei
AU  - Ma X
AUID- ORCID: 0000-0002-9148-5001
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Cancer Center, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 
      610041, Sichuan, China. drmaxuelei@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210526
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (CCR4 protein, human)
RN  - 0 (Receptors, CCR4)
RN  - YI437801BE (mogamulizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/etiology
MH  - Humans
MH  - Neoplasms/*drug therapy/mortality
MH  - Progression-Free Survival
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, CCR4/*antagonists & inhibitors
PMC - PMC8157723
OTO - NOTNLM
OT  - CCR4
OT  - Malignant lymphoma
OT  - Meta-analysis
OT  - Mogamulizumab
OT  - Solid tumors
COIS- The authors declare that they have no competing interests.
EDAT- 2021/05/28 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/05/26
CRDT- 2021/05/27 05:36
PHST- 2020/07/28 00:00 [received]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2021/05/27 05:36 [entrez]
PHST- 2021/05/28 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/05/26 00:00 [pmc-release]
AID - 10.1186/s12885-021-08363-w [pii]
AID - 8363 [pii]
AID - 10.1186/s12885-021-08363-w [doi]
PST - epublish
SO  - BMC Cancer. 2021 May 26;21(1):618. doi: 10.1186/s12885-021-08363-w.